Last updated: June 9, 2026
Suppliers for Loratadine and Pseudoephedrine Sulfate: API, Intermediates, and Finished-Dose Sources
Loratadine and pseudoephedrine sulfate are supplied through two distinct procurement tracks: (1) branded or generic finished-dose drug products with established commercial supply chains, and (2) upstream sourcing of APIs and key intermediates used to manufacture tablets and extended-release combinations. Supply is typically split between regulated API producers with GMP oversight and contract manufacturers that buy APIs and execute formulation, packaging, and distribution.
Fast procurement view (what most buyers buy):
- API: loratadine API; pseudoephedrine sulfate API (controlled in many jurisdictions).
- Intermediates: for pseudoephedrine routes (precursor chemicals) and for loratadine synthesis (benzyl/aryl intermediates).
- Finished dose: combination products (loratadine + pseudoephedrine sulfate), plus separate single-ingredient products.
Supply risk differentiators
- Regulatory/compliance controls: pseudoephedrine supply is subject to tighter controls due to diversion risk; supplier onboarding and audit requirements are usually stricter.
- Regional availability: some suppliers are strong in EU/India/Southeast Asia finished dose but weaker in US-facing DMF and cGMP API packages.
- Documentation: finished-dose programs often require full CMC traceability down to batch records, impurity profiles, and stability packages for the specific combination strength.
Below is a structured supplier landscape framework for loratadine + pseudoephedrine sulfate procurement, organized by what you can contractually buy (API vs finished dose), with the specific supplier roster dependent on the jurisdiction, dosage form, and whether you need DMF/US-suitable documentation.
Who manufactures loratadine and pseudoephedrine sulfate combination products by region?
Finished-dose combination supply for loratadine + pseudoephedrine sulfate is typically dominated by:
- brand and authorized generics in major markets,
- contract manufacturing networks for tablets and blister/bottle packaging,
- distributors with jurisdiction-specific import rights.
Typical finished-dose categories
- immediate-release tablets (common for combo cold/allergy regimens),
- OTC-channel branded products,
- generic tablets (same labeled strength, different holders).
Procurement pattern that drives supplier choice
- Buyers sourcing finished dose usually select based on:
- ability to supply the exact label strength,
- consistent batch-to-batch impurity control,
- packaging format (blister vs bottle) and labeling compliance,
- lead time and ability to support recalls and QMS audits.
Which companies supply loratadine API and what documentation do buyers require?
Loratadine API supply is relatively standard compared with pseudoephedrine due to fewer diversion controls. API procurement still hinges on:
- GMP status of the API site,
- impurity and polymorph/solid-form control,
- DMF readiness (if targeting US filings),
- CoA lot traceability and stability package access.
What procurement teams screen for (loratadine API)
- controlled manufacturing conditions and documented impurity limits,
- consistent crystal form / particle size distribution where relevant,
- regulatory inspection history for the API site,
- ability to support regulatory dossiers (DMF/ASMF and validation packages).
Which companies supply pseudoephedrine sulfate API and how are suppliers vetted?
Pseudoephedrine sulfate API supply is the higher-friction lane. Common supplier vetting requirements include:
- strict diversion-control compliance,
- enhanced customer qualification,
- audit rights for suspicious order monitoring,
- batch traceability and controlled-use documentation.
Typical compliance gates
- end-use declarations,
- customer licensing checks in the relevant jurisdiction,
- controlled procurement under quota-like constraints (where applicable),
- additional reporting for suspicious orders.
Operational consequence
- Many “nominal” API suppliers will not supply pseudoephedrine sulfate without a completed compliance onboarding.
How many APIs are required to make loratadine + pseudoephedrine sulfate tablets?
For combination tablets, the manufacturing bill of materials usually includes:
- loratadine API,
- pseudoephedrine sulfate API,
- excipients (binder, disintegrant, lubricant, coating components depending on tablet design),
- packaging materials (blisters or bottles, labeling, cartons).
Manufacturing implications
- API release testing and impurity control are critical for both actives.
- Pseudoephedrine sulfate can introduce additional impurity-management scrutiny tied to controlled-substance handling and route-specific byproducts.
What patent or regulatory constraints affect pseudoephedrine sourcing for combination products?
The supplier constraint for pseudoephedrine is less about product-specific patents and more about:
- diversion control regimes in the importing jurisdiction,
- controlled-substance precursor oversight frameworks,
- import-export licensing and recordkeeping rules.
Procurement consequence
- Even when a supplier can sell pseudoephedrine sulfate, buyers may face compliance delays before first receipt, and ongoing shipment can be impacted by administrative review.
What formulations are typically used in loratadine + pseudoephedrine sulfate tablets and does this change supplier selection?
Combination product formulation varies, but typical tablet design considerations drive supplier selection:
- immediate-release vs modified release,
- disintegration and dissolution targets,
- coating system and stability behavior with both actives.
Supplier selection impact
- Contract manufacturers that already run that exact combination format generally provide:
- faster tech transfer,
- validated dissolution pathways,
- established packaging and stability schedules.
How do finished-dose suppliers differ from contract manufacturers for this combination?
Finished-dose supplier (commercial distributor or brand/generic manufacturer)
- sells finished tablets with existing regulatory status and QA release workflows.
Contract manufacturer (CMO/CDMO)
- manufactures under a buyer’s authorization, often with:
- tech transfer,
- CMO-specific batch records,
- stability and process validation responsibilities defined by contract.
Key buyer decision
- If you need a quick supply chain, finished-dose is simpler.
- If you are launching or relabeling, CDMO route often dominates, with API sourcing locked early.
What is the Orange Book status of loratadine + pseudoephedrine sulfate combination products and why does it matter for suppliers?
Orange Book status affects who can legally sell generics or relabeled versions but does not directly determine API sourcing. Still, it affects:
- availability of authorized generics,
- timing of generic entry,
- the list of approved strengths and labeled indications.
Supplier impact
- If a product is under exclusivity or protected claims, the number of “safe” finished-dose suppliers shrinks.
- If patents are expired, more generic suppliers become commercially active.
What generic entry risks exist for loratadine + pseudoephedrine sulfate and how do they affect supply contracts?
Generic launch risks typically include:
- patent litigation outcomes that delay launch or trigger design-arounds,
- regulatory delays in ANDA approvals (if US),
- supply chain disruptions for pseudoephedrine due to compliance reviews.
Contract impact
- Many buyers use:
- supply contingencies tied to regulatory milestones,
- alternative sourcing clauses for pseudoephedrine API,
- buffer inventory requirements.
Key supplier procurement shortlist (API and finished dose): what buyers usually require
A compliant, high-speed supplier shortlist for this combination usually demands:
- GMP-certified API manufacturer for loratadine,
- compliant API manufacturer for pseudoephedrine sulfate with diversion controls,
- at least one CDMO with validated combination tablet experience,
- at least one finished-dose commercial supplier with established distribution coverage.
Procurement deliverables typically required in the supplier onboarding packet
- GMP certificates and inspection summaries,
- CoA templates and release specifications,
- impurity profiles and change control history,
- stability protocol access (for finished dose),
- audit/QMS credentials.
Key Takeaways
- Loratadine supply is a standard GMP API procurement lane; pseudoephedrine sulfate supply is a controlled-compliance lane.
- Combination product availability (finished-dose) depends on both patent/regulatory posture and diversion-control onboarding.
- Buyers should structure sourcing with at least two tiers: compliant pseudoephedrine API suppliers plus a CDMO or finished-dose supplier with proven combination tablet workflows.
- Contract terms should address compliance onboarding lead times and substitute-supplier options for pseudoephedrine sulfate.
FAQs
- Can a single supplier provide both loratadine and pseudoephedrine sulfate APIs for the same project?
- What documentation is typically required to qualify a pseudoephedrine sulfate API supplier for controlled distribution?
- Do pseudoephedrine sulfate API impurity profiles differ materially by manufacturing route and impact tablet dissolution?
- Should buyers source loratadine and pseudoephedrine sulfate from the same finished-dose supplier or separate API/CMO tracks?
- How does contract packaging format (blister vs bottle) affect ability to switch suppliers mid-contract?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. FDA. (Accessed 2026-06-09).
- FDA Guidance for Industry: Controlled Substance Ordering and Reporting Requirements (where applicable for precursor-related compliance frameworks). U.S. FDA. (Accessed 2026-06-09).
- WHO and ICH materials on GMP expectations for API manufacture and quality systems. ICH. (Accessed 2026-06-09).
